Analytical Data
-
Gene name
DSTN
- Application
-
Alternative Names
DSTN；ACTDP；DSN;Destrin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P60981
-
Expression Region
1-165aa
-
AA Sequence
MASGVQVADE VCRIFYDMKV RKCSTPEEIK KRKKAVIFCL SADKKCIIVE EGKEILVGDV GVTITDPFKH FVGMLPEKDC RYALYDASFE TKESRKEELM FFLWAPELAP LKSKMIYASS KDAIKKKFQG IKHECQANGP EDLNRACIAE KLGGSLIVAF EGCPVLEHHH HHH
-
Molecular Weight
20 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DSTN (Destrin) is a member of the gelsolin family of actin-binding proteins, playing a crucial role in regulating actin filament dynamics, which are essential for various cellular processes such as motility, division, and shape maintenance. Research on DSTN has gained momentum due to its involvement in a range of physiological and pathological conditions, including cancer metastasis and neurodegenerative diseases. The aberrant regulation or malfunction of DSTN can lead to disrupted cytoskeletal integrity, contributing to disease progression. Recent studies have focused on its molecular mechanisms, exploring how DSTN interacts with other proteins and the signaling pathways it influences. Additionally, researchers are investigating the potential of DSTN as a therapeutic target, as modulating its activity could result in novel approaches for treating conditions characterized by altered actin dynamics. Advances in recombinant protein technology have enabled the production of DSTN in controlled laboratory settings, allowing for in-depth structural and functional analyses. This groundwork is pivotal in understanding DSTN's role in cellular mechanics and its implications in disease, paving the way for new interventions in cancer and neurodegeneration.
